Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 11/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
| ▸ | HTR1B | P28222 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705085 | 0.83 | NR3C2 (0.50) | PGRNR3C1NR3C2HTR1ADRD2 | |
| SCHEMBL19629960 | 0.80 | NR3C2 (0.45) | PGRNR3C1NR3C2HTR1ADRD2 | |
| SCHEMBL8082246 | 0.80 | PGR (0.46) | PGRNR3C1NR3C2ARADRB1 | |
| SCHEMBL29939223 | 0.80 | NR3C2 (0.45) | PGRNR3C1NR3C2ARHTR1A | |
| SCHEMBL4102483 | 0.80 | NR3C2 (0.45) | PGRNR3C1NR3C2ARHTR1A | |
| SCHEMBL4480236 | 0.80 | PDE3B (0.41) | PGRNR3C1NR3C2HTR1ADRD2 | |
| SCHEMBL12116980 | 0.80 | PDE3B (0.53) | PGRNR3C1NR3C2HTR1AHTR1D | |
| SCHEMBL3174255 | 0.80 | IL4I1 (0.38) | PGRNR3C1NR3C2HTR1ADRD2 | |
| SCHEMBL21372202 | 0.80 | NR3C2 (0.48) | PGRNR3C1NR3C2HTR1AHTR1D | |
| SCHEMBL8202873 | 0.80 | NR3C2 (0.45) | PGRNR3C1NR3C2HTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| EP-4198034-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2023-06-21 | — | — | EP | disclosed |
| CN-115835867-A | Benzimidazole derivative, preparation method and medical application thereof | 上海拓界生物医药科技有限公司 | 2023-03-21 | — | — | CN | disclosed |
| WO-2022033567-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海拓界生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
| US-20210380570-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2021-12-09 | — | — | US | disclosed |
| EP-3790551-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019217307-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019217307-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | P2RX7, P2RX3, P2RX5 | PGR 1750/4885NR3C1 3201/4885NR3C2 3536/4885 |
| US-20210380570-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | PGR 4018/4885NR3C1 3333/4885NR3C2 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.